Translocator Protein 18 kDa (TSPO) as a Novel Therapeutic Target for Chronic Pain
Copyright © 2022 Jie Liu et al.
| Veröffentlicht in: | Neural plasticity. - 1998. - 2022(2022) vom: 30., Seite 8057854 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2022
|
| Zugriff auf das übergeordnete Werk: | Neural plasticity |
| Schlagworte: | Journal Article Review Research Support, Non-U.S. Gov't Carrier Proteins Ligands Receptors, GABA TSPO protein, human |
| Zusammenfassung: | Copyright © 2022 Jie Liu et al. Chronic pain is an enormous modern public health problem, with significant numbers of people debilitated by chronic pain from a variety of etiologies. Translocator protein 18 kDa (TSPO) was discovered in 1977 as a peripheral benzodiazepine receptor. It is a five transmembrane domain protein, mainly localized in the outer mitochondrial membrane. Recent and increasing studies have found changes in TSPO and its ligands in various chronic pain models. Reversing their expressions has been shown to alleviate chronic pain in these models, illustrating the effects of TSPO and its ligands. Herein, we review recent evidence and the mechanisms of TSPO in the development of chronic pain associated with peripheral nerve injury, spinal cord injury, cancer, and inflammatory responses. The cumulative evidence indicates that TSPO-based therapy may become an alternative strategy for treating chronic pain |
|---|---|
| Beschreibung: | Date Completed 09.09.2022 Date Revised 21.09.2022 published: Electronic-eCollection Citation Status MEDLINE |
| ISSN: | 1687-5443 |
| DOI: | 10.1155/2022/8057854 |